Sutro Biopharma (STRO) Accumulated Expenses (2017 - 2026)
Sutro Biopharma (STRO) posted Accumulated Expenses of $12.6 million for Q4 2025, down 63.67% sequentially from $34.7 million in Q3 2025, and down 2.38% YoY from $12.9 million in Q4 2024.
Sutro Biopharma (STRO) Accumulated Expenses (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported Accumulated Expenses for 9 years, with the latest figure at $12.6 million in Q4 2025.
- Quarterly Accumulated Expenses fell 2.38% year-over-year to $12.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.6 million (down 2.38% YoY) and the FY2025 annual result came in at $12.6 million, down 2.38% from the prior year.
- Accumulated Expenses eased to $12.6 million in Q4 2025 per STRO's latest filing, from $34.7 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $38.5 million in Q4 2023 and troughed at $4.5 million in Q1 2021.
- A 5-year average of $13.2 million and a median of $11.5 million in 2021 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses sank 66.46% in 2024, then jumped 163.16% in 2025.
- Over 5 years, Accumulated Expenses stood at $11.4 million in 2021, then gained by 29.32% to $14.8 million in 2022, then surged by 160.59% to $38.5 million in 2023, then tumbled by 66.46% to $12.9 million in 2024, then declined by 2.38% to $12.6 million in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $12.6 million, $34.7 million, and $11.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.24 Mn |
| Dec 31, 2025 | 12.60 Mn |
| Sep 30, 2025 | 34.68 Mn |
| Jun 30, 2025 | 11.76 Mn |
| Mar 31, 2025 | 11.55 Mn |
| Dec 31, 2024 | 12.91 Mn |
| Sep 30, 2024 | 13.18 Mn |
| Jun 30, 2024 | 9.94 Mn |
| Mar 31, 2024 | 7.08 Mn |
| Dec 31, 2023 | 38.47 Mn |
| Sep 30, 2023 | 11.37 Mn |
| Jun 30, 2023 | 19.59 Mn |
| Mar 31, 2023 | 12.39 Mn |
| Dec 31, 2022 | 14.76 Mn |
| Sep 30, 2022 | 10.38 Mn |
| Jun 30, 2022 | 7.75 Mn |
| Mar 31, 2022 | 5.41 Mn |
| Dec 31, 2021 | 11.42 Mn |
| Sep 30, 2021 | 8.49 Mn |
| Jun 30, 2021 | 6.51 Mn |